Guardant Health, Inc. (GH) 股票分析

公司概述

Guardant Health, Inc. operates as a precision oncology company that delivers comprehensive blood and tissue tests alongside specialized data sets to support oncology practices both within the United States and internationally. The core of its service offering includes the Guardant360 CDx test, which functions as a liquid biopsy solution for tumor mutation profiling, and the Guardant360 Liquid test, capable of measuring over 740 genes to assist in clinical decision-making. This enterprise functions within the Healthcare sector, specifically categorized under the Diagnostics & Research industry, positioning it as a provider of critical diagnostic infrastructure for cancer treatment monitoring. In terms of scale, the company holds a market capitalization of $11.43B and reports an annual revenue of $982.02M based on trailing twelve-month figures, supported by a workforce of 2,490 employees. These valuation and revenue metrics indicate that Guardant Health commands a significant market presence, reflecting high investor expectations for its technological platform despite the capital-intensive nature of developing and deploying advanced liquid biopsy technologies in a competitive global market.

财务健康

The company reported a trailing twelve-month revenue of $982.02M, yet it generated a net income of -$416,276,992 and an EBITDA of -$396,561,984, revealing a substantial gap between top-line growth and bottom-line profitability. This disparity highlights a cost structure where operational expenses, likely driven by research and development and commercialization efforts, significantly outpace earnings before interest, taxes, and depreciation. The free cash flow stands at -$88,105,872, which indicates that the company is currently burning cash to fund its growth initiatives rather than generating surplus liquidity from operations. Margin analysis shows a gross margin of 64.5%, suggesting efficient production or service delivery costs relative to revenue, while the operating margin of -42.9% and profit margin of -42.4% demonstrate that overhead costs are currently consuming the majority of gross profits. On the balance sheet, the company holds $1.20B in cash against $1.71B in debt, resulting in a debt-to-equity ratio that is not applicable due to the capital structure, suggesting a leveraged position where debt exceeds available cash reserves. Liquidity is supported by a current ratio of 4.84, indicating that the company possesses more than four times the current assets necessary to cover its short-term liabilities without immediate distress. Return on equity and return on assets are both not applicable, but the return on assets is recorded at -15.6%, which reveals that management is currently utilizing the asset base to generate negative returns, a common characteristic in the growth phase of biotechnology firms before profitability is achieved.

估值评估

The trailing P/E ratio is not applicable due to the lack of net income, while the forward P/E is listed at -140.56, implying that the market prices the stock based on anticipated future earnings rather than historical performance. The price-to-book ratio is -114.70, a negative figure that suggests the company's book value is negative or that the market is pricing the asset entirely on intangible future value rather than tangible net assets. Alternative valuation metrics such as the price-to-sales ratio of 11.64 and the EV/EBITDA of -30.12 indicate that investors are willing to pay a significant premium for revenue generation despite the current lack of profitability. Regarding trading range, the 52-week high is $120.74 and the 52-week low is $36.36; without the current share price explicitly provided in the facts, the relative position cannot be calculated, but the wide spread between the high and low demonstrates significant price volatility over the past year. The stock exhibits a beta of 1.65, which means its price volatility is 65% higher than the broader market, signaling that investors are exposed to elevated systemic risk when holding this position.

Growth & Income

Revenue growth year-over-year is recorded at 39.4%, whereas earnings growth is not applicable due to the company's net loss, indicating that revenue expansion is occurring without corresponding profit improvement. Since the company does not pay dividends, the dividend yield is not applicable and the payout ratio is 0.0%, meaning all available earnings are theoretically reinvested into the business or used to service debt rather than distributed to shareholders. The absence of dividend payments combined with negative free cash flow suggests a strategy focused entirely on capital expenditure and research investment to drive future market penetration rather than providing immediate income to investors. The overall growth and income profile reflects a high-risk, high-reward capital allocation strategy typical of late-stage biotechnology companies that prioritize market share and technological advancement over short-term financial returns.